Literature DB >> 14998623

Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation.

Yukiko Nakano1, Shumpei Niida, Keigo Dote, Sou Takenaka, Hidekazu Hirao, Fumiharu Miura, Mari Ishida, Tetsuji Shingu, Taijiro Sueda, Masao Yoshizumi, Kazuaki Chayama.   

Abstract

OBJECTIVES: The purpose of this study was to determine the relationship between matrix metalloproteinases (MMPs)-1, -2, and -9, and tissue inhibitors of metalloproteinases (TIMP)-1 and the atrial structural remodeling during atrial fibrillation (AF).
BACKGROUND: Matrix metalloproteinases, a family of proteolytic enzymes and TIMPs, regulate the extracellular matrix turnover in cardiac tissue.
METHODS: Tissue samples were obtained from 25 patients without a history of AF (regular sinus rhythm [RSR]) and 13 patients with AF (paroxysmal AF: 6, chronic AF 7) undergoing cardiac operations. We performed a western blotting analysis of the MMP-1, -2, and -9, and quantitatively analyzed the expression of the MMP-9 and TIMP-1 by real time polymerase chain reaction and ELISA. The localization of the MMP-9 was investigated by in situ zymography and immunohistochemistry.
RESULTS: The active form of the MMP-9 was significantly increased in the AF group in comparison to that in the RSR group (p < 0.05), but there were no differences between the groups in the protein level of the latent form of the MMP-9 and active and latent forms of the MMP-1 and MMP-2. We also demonstrated that the expression of the MMP-9 was significantly more increased in the atria of the AF group than in that of the RSR group for both the messenger ribonucleic acid (mRNA) (AF: RSR; 1: 1.5) and protein levels (AF: RSR; 3.9 +/- 1.3 : 1.5 +/- 0.4 ng/mg atrium). The expression level of the MMP-9 was also higher in the PAF group than in the RSR group, however, the diameter of the left atrium was similar in both groups. The gelatinase activity and left atrium diameter were positively correlated (p < 0.05, R = 0.766). The relative expression of the mRNA for the monocyte chemoattractant protein-1 was higher in the AF group than in the RSR group. Immunohistochemical analysis revealed that the MMP-9 was distributed within the perivascular area and under the epicardium of the atria.
CONCLUSIONS: We clearly showed that the expression of the MMP-9 increased in fibrillating atrial tissue, which may have contributed to the atrial structural remodeling and atrial dilatation during AF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14998623     DOI: 10.1016/j.jacc.2003.08.060

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Angiotensin II in atrial structural remodeling: the role of Ang II/JAK/STAT3 signaling pathway.

Authors:  Liuying Zheng; Xiaogang Jia; Cheng Zhang; Dong Wang; Zhongnan Cao; Jin Wang; Xinping Du
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

Review 2.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 3.  Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation.

Authors:  Stanley Nattel; Dobromir Dobrev
Journal:  Nat Rev Cardiol       Date:  2016-08-04       Impact factor: 32.419

Review 4.  Inflammation and the pathogenesis of atrial fibrillation.

Authors:  Yu-Feng Hu; Yi-Jen Chen; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Nat Rev Cardiol       Date:  2015-01-27       Impact factor: 32.419

5.  Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure.

Authors:  Ken W Lee; Thomas H Everett; Dulkon Rahmutula; Jose M Guerra; Emily Wilson; Chunhua Ding; Jeffrey E Olgin
Journal:  Circulation       Date:  2006-10-09       Impact factor: 29.690

6.  Long noncoding RNAs and novel inflammatory genes determined by RNA sequencing in human lymphocytes are up-regulated in permanent atrial fibrillation.

Authors:  Xue-Jing Yu; Li-Hui Zou; Jun-Hua Jin; Fei Xiao; Li Li; Nan Liu; Jie-Fu Yang; Tong Zou
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

Review 7.  Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation.

Authors:  Mohit K Turagam; Mahek Mirza; Paul H Werner; Jasbir Sra; David C Kress; A Jamil Tajik; Arshad Jahangir
Journal:  Cardiol Rev       Date:  2016 Mar-Apr       Impact factor: 2.644

Review 8.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

9.  Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation.

Authors:  Naoko Sasaki; Yasuo Okumura; Ichiro Watanabe; Hiroaki Mano; Koichi Nagashima; Kazumasa Sonoda; Rikitake Kogawa; Kimie Ohkubo; Toshiko Nakai; Atsushi Hirayama
Journal:  J Interv Card Electrophysiol       Date:  2014-02-20       Impact factor: 1.900

10.  Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.

Authors:  J Zhao; J Li; W Li; Y Li; H Shan; Y Gong; B Yang
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.